Charlotte Teunissen, PhD

Charlotte Teunissen aims to improve treatments for neurological diseases by developing fluid biomarkers for diagnosis, prognosis and monitoring of therapeutic responses. Her research group addresses the entire spectrum of biomarker development, including biomarker identification, assay development, analytical and clinical validation and implementation in clinical practice and trials. Her lab has extensive expertise with development of state-of-the-art technologies, such as ultrasensitive proteomics assays, in vitro diagnostics and biocomputation of large datasets. She chairs the biobank of the Amsterdam Dementia cohort, which contains more than 10000 paired spinal fluid and plasma/serum samples from individuals visiting the Alzheimer Center Amsterdam. She leads the Society for Neurochemistry, the Alzheimer’s Association Global Biomarker Standardization Consortium and the Coral proteomics consortium, and she is advisor for several public and private initiatives to implement fluid biomarkers in clinical practice and treatment development.